What is the average EBITDA multiple for an urgent care center?
Scope Research publishes three tiers for urgent care in its 2026 update: single centers and small portfolios (typically under $10M of revenue) at 3x to 7x EBITDA, regional multi-location operators ($10M to $50M of revenue) at 6x to 11x, and large platforms or operators with a value-based or virtual care strategy at 10x to 15x. The caveat Scope attaches to that top tier matters more than the number: the majority of the deals at the high end are from the mid 2010s.
Thinking about selling in the next one to three years?
Definition
An urgent care EBITDA multiple is the ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization that a buyer pays for an urgent care center or group.
The detail
Urgent care has no published index of transaction multiples, so the numbers come from the research and advisory firms that track the deals. Scope Research maintains a healthcare M&A valuation database and publishes an urgent care update; its 2026 edition sets out three tiers. Single centers and small portfolios, typically under $10M of revenue, "usually sell for lower multiples, ranging from 3x to 7x EBITDA," which Scope attributes to higher operational risk, limited geographic reach, low barriers to entry and heavy reliance on the owner-operator. Regional multi-location operators with $10M to $50M of revenue and proven profitability "can range from 6x to 11x EBITDA, depending on size, local market conditions, service mix, growth rate, and the stability of the cash flow." Companies with considerable scale, or a value-based care or virtual care strategy and a management team that stays, "can command multiples in the 10x to 15x EBITDA range." Read that top tier with the caveat Scope attaches to it, because it is the most useful sentence published on the topic: the majority of the deals at the high end of that range are from the mid 2010s. A 15x comparable from 2016 is not a 2026 offer. Scope does report recent deals in its database with EBITDA multiples up to 16.7x, so the ceiling exists, but it is rare and it is not a planning assumption. Scope's revenue bands are approximate (it says "typically" for the first tier) and the top tier has none, so place yourself by revenue, by adjusted EBITDA and by whether the business runs without you. One market fact frames the rest. Scope reports announced urgent care M&A deals fell from a peak of 44 in 2021 to 29 in 2025, so this is a thinner buyer market than the roll-up years. We publish no EBITDA-margin benchmark for urgent care, because no source we could open states one, and a margin borrowed from another specialty would not be a benchmark. Worked example on Scope's tiers: a two-site operator under $10M of revenue with $600K of adjusted EBITDA sits in the bottom tier, so 3x to 7x puts it at $1.8M to $4.2M. Grow the same operator past $10M of revenue and to $2.5M of adjusted EBITDA and it moves to the middle tier at 6x to 11x, or $15M to $27.5M. The bottom of the range doubles (3x to 6x), the top rises from 7x to 11x, and both apply to about four times the earnings, which is why scale is the lift. Work out your adjusted EBITDA first, because the earnings figure you negotiate from moves the outcome more than the multiple does.
| Operator profile | Published multiple | Source |
|---|---|---|
| Single center / small portfolio (typically under $10M revenue) | 3x – 7x EBITDA | Scope Research (2026) |
| Regional multi-location operator ($10M–$50M revenue) | 6x – 11x EBITDA | Scope Research (2026) |
| Large platform, value-based care or tech-driven operator | 10x – 15x EBITDA | Scope Research (2026) |
| Single-location asking price (25th–75th percentile) | 0.7x – 1.3x revenue | Scope Research (2026) |
No index publishes urgent care transaction multiples; every row is Scope Research's own published figure. Scope attaches approximate revenue bands to its first two tiers (typically under $10M, and $10M to $50M) and none to the top tier, and it warns that the majority of deals at the high end of the 10x to 15x tier are from the mid 2010s. The asking-price row comes from listings of single-location centers for sale, so it shows what sellers ask, not what buyers paid.
Single centers and small portfolios (typically under $10M of revenue) "usually sell for lower multiples, ranging from 3x to 7x EBITDA," which Scope attributes to operational risk, limited geographic reach, low barriers to entry and reliance on the owner-operator.
Source: Scope Research: Urgent Care Valuation Multiples and M&A Trends 2026
Regional multi-location operators ($10M to $50M of revenue) with proven profitability "can range from 6x to 11x EBITDA, depending on size, local market conditions, service mix, growth rate, and the stability of the cash flow."
Source: Scope Research: Urgent Care Valuation Multiples and M&A Trends 2026
Operators with considerable scale or a value-based and virtual care strategy "can command multiples in the 10x to 15x EBITDA range," but Scope notes the majority of the deals at the high end of that range are from the mid 2010s. Its database includes recent deals with reported multiples up to 16.7x.
Source: Scope Research: Urgent Care Valuation Multiples and M&A Trends 2026
Announced urgent care M&A deals fell from a peak of 44 in 2021 to 29 in 2025.
Source: Scope Research: Urgent Care Valuation Multiples and M&A Trends 2026
Small single-location urgent care centers are listed for sale between 0.7x and 1.3x revenue at the 25th and 75th percentiles, and between 3.3x and 5x owner cash flow.
Source: Scope Research: Urgent Care Valuation Multiples and M&A Trends 2026
What this means for clinic owners
From Sorso
The tier you sit in is set by scale, which Scope marks at about $10M of revenue between its first two tiers, and by whether the business runs without you. Scope prices its bottom tier down for owner-operator reliance and low barriers to entry, and neither of those is about clinical quality. You cannot change the barriers to entry, but you can make the business run without you. Before you anchor on a headline multiple, check the date on the comparable. The 15x prints are largely a decade old and the annual deal count has fallen by a third since 2021, so the realistic question for a single-site owner is whether added sites can take the business into the second tier, not whether it can reach the third. Getting there is a finance project: normalized EBITDA, location-level P&Ls and a payer mix a buyer believes, which is what fractional CFO support for urgent care is for.
Talk it through
Want Stan to look at this for your clinic?
Book a free 30-minute call with Stan Sukhinin, CFA. Bring the question and, if you have it, last month's P&L. He will tell you what he would check first.
Continue with Sorso
How clinic owners typically work with us after a question like this
Urgent Care Accounting & CFO
Built for urgent care economics
Per-visit cost, payer contracting, de novo ramp, and multi-site P&L — for urgent care owners. From $2,000/mo.
Explore your specialty →Accounting
Healthcare-specialist accounting
Books done right by people who understand clinic finance. Starts at $2,000/mo.
Explore Accounting →Free Assessment
See where your clinic stands
4-minute, 15-question diagnostic. Personalized scorecard emailed to you.
Take the Free Assessment →Related questions
How do PE firms value medical practices?
Private equity firms value a medical practice as a multiple of its trailing-twelve-month adjusted EBITDA, and the multiple rises with scale. Published ladders run from 2.5–4x for a single owner-operated physical therapy clinic (Breakwater M&A) to 10x–20x for large primary care platforms (Scope Research), and payer mix, growth and owner dependence move a practice within its band.
What is the difference between platform and add-on multiples?
Platform acquisitions trade at higher EBITDA multiples than add-ons because the buyer is paying for scale, management and a base to acquire from, while an add-on brings its earnings into a platform that already has those things. In dental, FOCUS Investment Banking puts platform investments at 9–11× EBITDA and add-on acquisitions at 5–8×.
What are EBITDA add-backs in practice valuation?
EBITDA add-backs are non-recurring or owner-related expenses added back to reported EBITDA to show normalized earnings, the figure a buyer applies its multiple to. In an owner-operated practice they usually cover above-market owner pay, personal expenses run through the business, one-time costs and pro forma adjustments, and each one needs documents to survive a buyer's diligence.
How long does it take to sell a medical practice?
Selling a medical practice to a PE buyer usually takes about six to nine months from hiring an advisor to closing. FOCUS Investment Banking says its healthcare sell-side process typically takes 6 months, and broker Raincatcher puts a clinic or small-group sale at six to nine months: preparation and valuation in months one to two, marketing and offers in months two to five, and diligence, licensing and closing in months five to nine.
Founder of Sorso and a CFA charterholder. Before Sorso, Stan spent 19 years in corporate finance at institutions including UniCredit and Société Générale — managing a $450M loan portfolio and making senior partner at a major mezzanine lender by 29 — then built a fractional CFO firm exclusively for outpatient healthcare clinics.
Want to see how your practice measures up?
Take the 4-minute financial assessment. It is free, and it will show you where your practice is leaking money.